Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: NOW who wrote (34142)	11/6/2000 1:11:04 PM
From: LLCF	Read Replies (1) \| Respond to of 436258

<Did you happen to notice it performed no better than ibuprofen? > Not yet... wait till the next phase! HO ho... they'll dream a good trial up. DAK

To: NOW who wrote (34142)	11/6/2000 3:12:16 PM
From: Archie Meeties	Read Replies (2) \| Respond to of 436258

Not the point. The whole reason for selective cox2i is avoiding the nasty tendency of common NSAIDS (which inhibit all cox) to contribute to ulcers (That and shorting JPM).

To: NOW who wrote (34142)	11/6/2000 6:42:25 PM
From: Ilaine	Read Replies (2) \| Respond to of 436258

The beauty of Cox-2 inhibitors, like Vioxx and Celebrex, is that they don't cause internal bleeding, like regular NSAIDS. It doesn't matter to most people, but if you have to take NSAIDS every day, something like 40,000 people are hospitalized every year in the US for internal bleeding caused by NSAIDS and 3,000 die. I have rheumatoid arthritis and take a lot of pills. Ibuprofen used to really tear up my stomach, so I am very happy with Celebrex. The FDA won't let Searle Pfizer say it, but Celebrex actually kills pain much much better, too. It's so subjective I don't think they can measure it meaningfully, it's just anecdotal. I am also glad my HMO lets me have it for $7 a bottle, the street price is ridiculous (roughly $300).